Allurion Technologies reported third-quarter revenues of $2.7 million, reflecting a strategic shift in focus to a comprehensive obesity management strategy. The company successfully passed several key FDA inspection milestones, signaling progress towards the approval of their Smart Capsule.

• Revenue of $2.7 million was impacted by a strategic restructuring to enhance focus on customer accounts promoting combined treatments with GLP-1s.
• Operating expenses decreased by 29% year-over-year to $10.9 million, resulting in a narrowed operating loss of $9.6 million, down 22% from the previous year.
• The restructuring aims to position Allurion for long-term growth, particularly as they anticipate new patient influx from patients discontinuing GLP-1 treatments.
• Allurion is transitioning towards a debt-free structure, exchanging outstanding debt for convertible equity while securing additional financing to strengthen its balance sheet.
• The company is exploring innovative R&D initiatives, including a drug-eluting balloon in collaboration with a strategic partner, potentially revolutionizing obesity therapy.